Business context and reporting period
Filing identity: The supplied filing is Ocuphire Pharma, Inc. (Nasdaq: OCUP), not Opus Genetics, Inc. It is an unaudited Form 10-Q for the quarter and six months ended June 30, 2021. Ocuphire is a clinical-stage ophthalmic biotech developing Nyxol and APX3330; it had no approved products and reported only limited collaboration revenue.
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are rounded to millions unless noted.
| Metric | Q2 2021 | Six months 2021 | Comparable 2020 |
|---|---|---|---|
| Collaboration revenue | $0.1m | $0.1m | $0 |
| General and administrative expense | $3.4m | $5.1m | Q2 $0.6m; six months $0.9m |
| Research and development expense | $3.8m | $7.3m | Q2 $0.7m; six months $0.9m |
| Operating loss | $7.1m | $12.3m | Q2 $1.3m; six months $4.0m |
| Net loss | $7.1m | $46.2m | Q2 $1.6m; six months $4.7m |
| Basic and diluted loss per share | $(0.52) | $(3.76) | Q2 $(0.43); six months $(1.29) |
| Operating cash used | Not separately stated | $10.1m | Six months $1.4m |
At June 30, cash and cash equivalents were $24.2m, current assets $25.2m, current liabilities $2.7m, and stockholders’ equity $22.6m. There were no warrant liabilities on the balance sheet and the prior convertible notes had converted to equity; the filing reports no outstanding convertible-note debt at period-end. Accumulated deficit was $78.8m. No meaningful product gross margin was reported.
Material changes and unusual items
- Operating expenses rose substantially year over year as clinical trials, manufacturing, regulatory work, staffing, public-company costs, insurance and legal costs increased.
- Six-month net loss included a $33.8m noncash warrant-liability fair-value expense. Series A warrants were reclassified from liabilities to equity in February 2021 after investors waived reset provisions; the resulting accounting charge materially increased reported loss but was not an equivalent operating cash outflow.
- Financing raised $15.0m gross in a June registered direct offering and about $4.1m gross through the ATM program during the first half. Financing cash flow was $18.0m net of costs. These issuances and warrant exercises increased shares outstanding; 16.9m shares were outstanding at June 30.
- In May, Ocuphire issued 350,000 shares valued at $1.6m to settle potential investor claims; the charge was recorded in general and administrative expense.
- On June 16, the company signed a Processa license for RX-3117 outside the BioSense territory. The upfront consideration—44,689 Processa shares and $200,000 cash—was received in July, after quarter-end; no related revenue was recognized by June 30.
Outlook, risks and contingencies
- Management expects continued operating losses and higher research and development costs. It expects to fund operations through additional equity or debt, collaborations, partnerships or licensing; it has no committed external funding source.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern. The company said it had raised $18.0m net from the first-half offerings since the auditor’s 2020 going-concern report, but additional capital remains necessary and may not be available on acceptable terms.
- Clinical milestones described include Nyxol Phase 3 work for reversal of pharmacologically induced mydriasis and night-vision disturbance, planned MIRA-3/MIRA-4 studies, and APX3330 Phase 2 enrollment begun in April 2021. Management anticipated Nyxol trial results in early 2022 and, if trials succeeded, an NDA filing in late 2022; these are forward-looking targets, not guarantees. VEGA-1 presbyopia results were reported as positive, with further pivotal-trial planning underway.
- COVID-19 could disrupt manufacturing, supply chains, research, trial enrollment and regulatory activity, and may adversely affect liquidity and operations. Clinical outcomes, trial timing, regulatory decisions and financing availability remain significant uncertainties.
- Potential future Apexian sublicense milestones total up to $11m for development and regulatory events and up to $20m for sales milestones, plus single-digit royalties; none had been triggered or accrued at June 30. BioSense milestone payments of up to $84.5m and royalties are also contingent. No material legal proceedings were identified; a settlement was completed as noted above.
- Management reported disclosure controls and procedures were effective as of June 30, 2021, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for Ocuphire Pharma, not Opus Genetics.
- Assess cash runway against the $10.1m first-half operating cash use, planned trial spending and the company’s stated going-concern uncertainty; the filing does not give a definitive cash-runway estimate.
- Track share and warrant dilution, including 5.7m Series A warrants, 1.5m June-offering warrants and remaining Series B warrants, as well as future capital-raising needs.
- Verify clinical-trial progress, results and regulatory timelines against management’s forward-looking dates.
- Distinguish recurring operating performance from the $33.8m noncash warrant remeasurement charge and the one-time settlement expense.
- Monitor whether contingent license milestones, royalties and the post-quarter Processa consideration are earned, received and recognized.